Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study
Uloženo v:
| Název: | Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study |
|---|---|
| Autoři: | Barros, Fernando, Gunier, Robert, Rego, Albertina, Sentilhes, Loïc, Rauch, Stephen, Gandino, Serena, Maiz, Nerea |
| Přispěvatelé: | Institut Català de la Salut, Barros FC Post Graduate Program in Health in the Life Cycle, Universidade Católica de Pelotas, Pelotas, Brazil. Gunier RB, Rauch S School of Public Health, University of California, Berkeley, CA. Rego A Departamento de Pediatria, Faculdade Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Sentilhes L Department of Obstetrics and Gynecology, Bordeaux University Hospital, Bordeaux, France. Gandino S Nuffield Department of Women’s & Reproductive Health, University of Oxford, Oxford, United Kingdom. Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, United Kingdom. Maiz N Unitat de Medicina Fetal, Servei d’Obstetrícia i Medicina Reproductiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Zdroj: | Scientia |
| Informace o vydavateli: | Elsevier |
| Rok vydání: | 2024 |
| Témata: | COVID-19 (Malaltia) - Vacunació, Avaluació de resultats (Assistència sanitària), Embaràs, Infants nadons, DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections, Other subheadings::Other subheadings::Other subheadings::/prevention & control, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Pregnancy Outcome, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination, ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus, Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del embarazo, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación |
| Popis: | Maternal vaccination; COVID-19; Neonatal outcomes ; Vacunació materna; COVID-19; Resultats neonatals ; Vacunación materna; COVID-19; Resultados neonatales ; Background In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk for severe COVID-19–related complications and maternal morbidity and mortality. Objective This study aimed to analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes when Omicron was the variant of concern. Study Design INTERCOVID-2022 was a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes and to assess vaccine effectiveness. Women diagnosed with laboratory-confirmed COVID-19 during pregnancy were compared with 2 nondiagnosed, unmatched women recruited concomitantly and consecutively during pregnancy or at delivery. Mother-newborn dyads were followed until hospital discharge. The primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index, severe perinatal morbidity and mortality index, preterm birth, neonatal death, referral to neonatal intensive care unit, and diseases during the neonatal period. Vaccine effectiveness was estimated with adjustment for maternal risk profile. Results We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) nondiagnosed mothers. Among the diagnosed mothers, 642 (40.7%) were not vaccinated, 147 (9.3%) were partially vaccinated, 551 (34.9%) were completely vaccinated, and 237 (15.0%) also had a booster vaccine. Neonates of booster-vaccinated mothers had less than half (relative risk, 0.46; 95% confidence interval, 0.23–0.91) the risk of being diagnosed with COVID-19 when compared with those of unvaccinated mothers; ... |
| Druh dokumentu: | article in journal/newspaper |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| Relation: | American Journal of Obstetrics and Gynecology;231(4); https://doi.org/10.1016/j.ajog.2024.02.008; https://hdl.handle.net/11351/11971 |
| DOI: | 10.1016/j.ajog.2024.02.008 |
| Dostupnost: | https://hdl.handle.net/11351/11971 https://doi.org/10.1016/j.ajog.2024.02.008 |
| Rights: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/openAccess |
| Přístupové číslo: | edsbas.2FB2DE2 |
| Databáze: | BASE |
Nájsť tento článok vo Web of Science | Abstrakt: | Maternal vaccination; COVID-19; Neonatal outcomes ; Vacunació materna; COVID-19; Resultats neonatals ; Vacunación materna; COVID-19; Resultados neonatales ; Background In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk for severe COVID-19–related complications and maternal morbidity and mortality. Objective This study aimed to analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes when Omicron was the variant of concern. Study Design INTERCOVID-2022 was a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes and to assess vaccine effectiveness. Women diagnosed with laboratory-confirmed COVID-19 during pregnancy were compared with 2 nondiagnosed, unmatched women recruited concomitantly and consecutively during pregnancy or at delivery. Mother-newborn dyads were followed until hospital discharge. The primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index, severe perinatal morbidity and mortality index, preterm birth, neonatal death, referral to neonatal intensive care unit, and diseases during the neonatal period. Vaccine effectiveness was estimated with adjustment for maternal risk profile. Results We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) nondiagnosed mothers. Among the diagnosed mothers, 642 (40.7%) were not vaccinated, 147 (9.3%) were partially vaccinated, 551 (34.9%) were completely vaccinated, and 237 (15.0%) also had a booster vaccine. Neonates of booster-vaccinated mothers had less than half (relative risk, 0.46; 95% confidence interval, 0.23–0.91) the risk of being diagnosed with COVID-19 when compared with those of unvaccinated mothers; ... |
|---|---|
| DOI: | 10.1016/j.ajog.2024.02.008 |